Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.
Sareum's most advanced development programme (Chk1) was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.